Jonathan G Drachman insider trades: Calithera Biosciences (CALA) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jonathan reports to the SEC
Open-market buys and sales
19 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 10, 2021 | CALA | ↑ Buy | 200,000 | $0.86 | $172K | Direct | Nov 10, 2021 (0d) |
| Aug 25, 2021 | NLTX | ↑ Buy | 25,000 | $6.45 | $161K | Indirect | Aug 26, 2021 (1d) |
| Aug 24, 2021 | NLTX | ↑ Buy | 100,000 | $6.11 | $611K | Direct | Aug 26, 2021 (2d) |
| Jun 4, 2021 | NLTX | ↑ Buy | 50,000 | $9.51 | $475K | Direct | Jun 7, 2021 (3d) |
| Dec 20, 2019 | NLTX | ↑ Buy | 119,047 | $8.40 | $1000K | Direct | Dec 20, 2019 (0d) |
| Sep 11, 2019 | NLTX | ↑ Buy | 250,000 | $3.13 | $782K | Direct | Sep 11, 2019 (0d) |
| Mar 5, 2018 | SGEN | ↓ Sell | 10,457 | $52.83 | $552K | Direct | Mar 7, 2018 (2d) |
| Aug 28, 2017 | SGEN | ↓ Sell | 8,502 | $47.89 | $407K | Direct | Aug 30, 2017 (2d) |
| Aug 24, 2017 | SGEN | ↓ Sell | 10,000 | $47.54 | $475K | Direct | Aug 25, 2017 (1d) |
| Jul 27, 2017 | SGEN | ↓ Sell | 10,000 | $54.54 | $545K | Direct | Jul 31, 2017 (4d) |
| Jun 22, 2017 | SGEN | ↓ Sell | 10,000 | $64.01 | $640K | Direct | Jun 26, 2017 (4d) |
| Nov 9, 2016 | SGEN | ↓ Sell | 7,751 | $66.75 | $517K | Direct | Nov 14, 2016 (5d) |
| Nov 1, 2016 | SGEN | ↓ Sell10b5-1 | 3,418 | $51.74 | $177K | Direct | Nov 3, 2016 (2d) |
| Sep 22, 2016 | SGEN | ↓ Sell | 2,249 | $56.75 | $128K | Direct | Sep 23, 2016 (1d) |
| Aug 22, 2016 | SGEN | ↓ Sell | 3,991 | $46.59 | $186K | Direct | Aug 22, 2016 (0d) |
| Aug 20, 2015 | SGEN | ↓ Sell | 4,462 | $42.02 | $188K | Direct | Aug 25, 2015 (5d) |
| Aug 24, 2014 | SGEN | ↓ Sell | 2,772 | $43.55 | $121K | Direct | Aug 27, 2014 (3d) |
| Feb 20, 2014 | SGEN | ↓ Sell | 1,241 | $53.25 | $66K | Direct | Feb 24, 2014 (4d) |
| Jan 16, 2014 | SGEN | ↓ Sell | 1,201 | $45.75 | $55K | Direct | Jan 21, 2014 (5d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Jonathan G Drachman's insider trades
Jonathan G Drachman is a director at Calithera Biosciences (CALA). Since Jan 16, 2014, Jonathan has reported 6 open-market purchases worth $3.2M and 13 sales worth $4.1M on SEC Form 4. There have been no open-market trades in the last 12 months.
1 sale (4% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.
Their filings also include grants and awards (26 filings), option exercises (11 filings), shares returned to the company (1 filing), conversions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CALA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.